Literature DB >> 24366882

Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Alison M Karst1, Paul M Jones, Natalie Vena, Azra H Ligon, Joyce F Liu, Michelle S Hirsch, Dariush Etemadmoghadam, David D L Bowtell, Ronny Drapkin.   

Abstract

The fallopian tube is now generally considered the dominant site of origin for high-grade serous ovarian carcinoma. However, the molecular pathogenesis of fallopian tube-derived serous carcinomas is poorly understood and there are few experimental studies examining the transformation of human fallopian tube cells. Prompted by recent genomic analyses that identified cyclin E1 (CCNE1) gene amplification as a candidate oncogenic driver in high-grade serous ovarian carcinoma, we evaluated the functional role of cyclin E1 in serous carcinogenesis. Cyclin E1 was expressed in early- and late-stage human tumor samples. In primary human fallopian tube secretory epithelial cells, cyclin E1 expression imparted malignant characteristics to untransformed cells if p53 was compromised, promoting an accumulation of DNA damage and altered transcription of DNA damage response genes related to DNA replication stress. Together, our findings corroborate the hypothesis that cyclin E1 dysregulation acts to drive malignant transformation in fallopian tube secretory cells that are the site of origin of high-grade serous ovarian carcinomas. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24366882      PMCID: PMC4517944          DOI: 10.1158/0008-5472.CAN-13-2247

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

2.  p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation.

Authors:  Alex C Minella; Jherek Swanger; Eileen Bryant; Markus Welcker; Harry Hwang; Bruce E Clurman
Journal:  Curr Biol       Date:  2002-10-29       Impact factor: 10.834

3.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

Review 4.  A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube.

Authors:  Mitra Mehrad; Gang Ning; Eleanor Y Chen; Karishma K Mehra; Christopher Paul Crum
Journal:  Adv Anat Pathol       Date:  2010-09       Impact factor: 3.875

5.  MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E.

Authors:  Matan Ofir; Dalia Hacohen; Doron Ginsberg
Journal:  Mol Cancer Res       Date:  2011-03-31       Impact factor: 5.852

6.  A mouse model for cyclin E-dependent genetic instability and tumorigenesis.

Authors:  Keith R Loeb; Heather Kostner; Eduardo Firpo; Thomas Norwood; Karen D Tsuchiya; Bruce E Clurman; James M Roberts
Journal:  Cancer Cell       Date:  2005-07       Impact factor: 31.743

Review 7.  The genesis and evolution of high-grade serous ovarian cancer.

Authors:  David D L Bowtell
Journal:  Nat Rev Cancer       Date:  2010-10-14       Impact factor: 60.716

8.  Serous carcinogenesis in the fallopian tube: a descriptive classification.

Authors:  Elke Jarboe; Ann Folkins; Marisa R Nucci; David Kindelberger; Ronny Drapkin; Alexander Miron; Yonghee Lee; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2008-01       Impact factor: 2.762

9.  Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.

Authors:  Joyce F Liu; Michelle S Hirsch; Hang Lee; Ursula A Matulonis
Journal:  Gynecol Oncol       Date:  2009-09-30       Impact factor: 5.482

10.  Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.

Authors:  Dariush Etemadmoghadam; Anna deFazio; Rameen Beroukhim; Craig Mermel; Joshy George; Gad Getz; Richard Tothill; Aikou Okamoto; Maria B Raeder; Paul Harnett; Stephen Lade; Lars A Akslen; Anna V Tinker; Bianca Locandro; Kathryn Alsop; Yoke-Eng Chiew; Nadia Traficante; Sian Fereday; Daryl Johnson; Stephen Fox; William Sellers; Mitsuyoshi Urashima; Helga B Salvesen; Matthew Meyerson; David Bowtell
Journal:  Clin Cancer Res       Date:  2009-02-03       Impact factor: 12.531

View more
  63 in total

Review 1.  The history and future of targeting cyclin-dependent kinases in cancer therapy.

Authors:  Uzma Asghar; Agnieszka K Witkiewicz; Nicholas C Turner; Erik S Knudsen
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

2.  Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging.

Authors:  Naveena Singh; Asma Faruqi; Friedrich Kommoss; W Glenn McCluggage; Giorgia Trevisan; Janine Senz; Amy Lum; C Blake Gilks; Michael Anglesio
Journal:  Mod Pathol       Date:  2017-11-17       Impact factor: 7.842

3.  Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.

Authors:  Jihun Kim; Cameron Fox; Shouyong Peng; Mark Pusung; Eirini Pectasides; Eric Matthee; Yong Sang Hong; In-Gu Do; Jiryeon Jang; Aaron R Thorner; Paul Van Hummelen; Anil K Rustgi; Kwok-Kin Wong; Zhongren Zhou; Ping Tang; Kyoung-Mee Kim; Jeeyun Lee; Adam J Bass
Journal:  J Clin Invest       Date:  2014-11-17       Impact factor: 14.808

4.  Tumour-suppressive microRNA-424-5p directly targets CCNE1 as potential prognostic markers in epithelial ovarian cancer.

Authors:  Jingjing Liu; Zhenpeng Gu; Yujie Tang; Junmei Hao; Cuiping Zhang; Xingsheng Yang
Journal:  Cell Cycle       Date:  2018-01-02       Impact factor: 4.534

5.  Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.

Authors:  Suming Wang; Anna Blois; Tina El Rayes; Joyce F Liu; Michelle S Hirsch; Karsten Gravdal; Sangeetha Palakurthi; Diane R Bielenberg; Lars A Akslen; Ronny Drapkin; Vivek Mittal; Randolph S Watnick
Journal:  Sci Transl Med       Date:  2016-03-09       Impact factor: 17.956

Review 6.  Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.

Authors:  Tova M Bergsten; Joanna E Burdette; Matthew Dean
Journal:  Cancer Lett       Date:  2020-02-15       Impact factor: 8.679

7.  Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

Authors:  George Au-Yeung; Franziska Lang; Walid J Azar; Chris Mitchell; Kate E Jarman; Kurt Lackovic; Diar Aziz; Carleen Cullinane; Richard B Pearson; Linda Mileshkin; Danny Rischin; Alison M Karst; Ronny Drapkin; Dariush Etemadmoghadam; David D L Bowtell
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

8.  Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.

Authors:  Andrew J Wilson; Kofi Sarfo-Kantanka; Toby Barrack; Alexandra Steck; Jeanette Saskowski; Marta A Crispens; Dineo Khabele
Journal:  Gynecol Oncol       Date:  2016-07-19       Impact factor: 5.482

9.  Regulatory network involving miRNAs and genes in serous ovarian carcinoma.

Authors:  Haiyan Zhao; Hao Xu; Luchen Xue
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

10.  ATR inhibition preferentially targets homologous recombination-deficient tumor cells.

Authors:  M Krajewska; R S N Fehrmann; P M Schoonen; S Labib; E G E de Vries; L Franke; M A T M van Vugt
Journal:  Oncogene       Date:  2014-09-01       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.